Natriuretic peptides and soluble ST2 improves echocardiographic diagnosis of elevated left ventricular filling pressures.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
27 Sep 2024
Historique:
received: 02 07 2024
accepted: 17 09 2024
medline: 28 9 2024
pubmed: 28 9 2024
entrez: 27 9 2024
Statut: epublish

Résumé

Elevated filling pressure of the left ventricle (LV) defines diastolic dysfunction. The gold standard for diagnosis is represented by the measurement of LV end-diastolic pressure (LVEDP) during cardiac catheterization, but it has the disadvantage of being an invasive procedure. This study aimed to investigate the correlation between LVEDP and cardiac serum biomarkers such as natriuretic peptides (mid-regional pro-atrial natriuretic peptide [MR-proANP], B-type natriuretic peptide [BNP], and N-terminal prohormone BNP [NT-proBNP]), soluble ST2 (sST2), galectin-3 and mid-regional pro-adrenomedullin (MR-proAMD). Consecutive patients hospitalized in a tertiary center and undergoing left cardiac catheterization were included in the study. Diastolic dysfunction was considered present if the end-expiratory LVEDP was ≥ 15 mmHg. Cardiac biomarkers were determined from pre-procedural peripheral venous blood samples. A total of 110 patients were included, of whom 76 (69.0%) were males, with a median age of 65 (55-71) years. Median LVEDP was 13.5 (8-19) mmHg and diastolic dysfunction was present in 50 (45.4%) of the patients. LVEDP correlated with BNP (p < 0.0001, r = 0.39 [0.20-0.53]), NT-proBNP (p < 0.0001, r = 0.40 [0.22-0.55]), MR-proANP (p = 0.001, r = 0.30 [0.11-0.46]), sST2 (p < 0.0001, r = 0.47 [0.30-0.60]), but not with MR-proAMD (p = 0.77) or galectin-3 (p = 0.76). In the final stepwise multivariable binary logistic regression model, diastolic dysfunction was predicted by NT-proBNP, mitral average E/e', sST2, atrial fibrillation, and left atrium reservoir strain. BNP, NT-proBNP, MR-proANP, and sST2 had predictive value for diastolic dysfunction. In contrast, galectin-3 and MR-proAMD were not associated with increased filling pressures. Furthermore, NT-proBNP and sST2 significantly improved diastolic dysfunction prediction in the final multivariable model.

Identifiants

pubmed: 39333652
doi: 10.1038/s41598-024-73349-0
pii: 10.1038/s41598-024-73349-0
doi:

Substances chimiques

Interleukin-1 Receptor-Like 1 Protein 0
IL1RL1 protein, human 0
Biomarkers 0
Natriuretic Peptide, Brain 114471-18-0
Galectin 3 0
Peptide Fragments 0
pro-brain natriuretic peptide (1-76) 0
Natriuretic Peptides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

22171

Subventions

Organisme : Universitatea de Medicină, Farmacie, Științe și Tehnologie "George Emil Palade" din Târgu Mureș
ID : 164/9/10.01.2023

Informations de copyright

© 2024. The Author(s).

Références

McDonagh, T. A. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart J. 42, 3599–3726 (2021). (2021).
Galderisi, M. et al. European multicentre validation study of the accuracy of E/e′ ratio in estimating invasive left ventricular filling pressure: EURO-FILLING study. Eur. Heart J. - Cardiovasc. Imaging. 15, 810–816 (2014).
doi: 10.1093/ehjci/jeu022 pubmed: 24596053
Lancellotti, P. et al. Echo-Doppler estimation of left ventricular filling pressure: results of the multicentre EACVI Euro-Filling study. Eur. Heart J. - Cardiovasc. Imaging. 18, 961–968 (2017).
doi: 10.1093/ehjci/jex067 pubmed: 28444160
Nauta, J. F. et al. Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: a systematic review in patients with heart failure with preserved ejection fraction. Eur. J. Heart Fail.20, 1303–1311 (2018).
doi: 10.1002/ejhf.1220 pubmed: 29877602
Sharifov, O. F., Schiros, C. G., Aban, I., Denney, T. S. & Gupta, H. Diagnostic accuracy of tissue Doppler Index E/e’ for evaluating left ventricular filling pressure and diastolic Dysfunction/Heart failure with preserved ejection fraction: a systematic review and Meta-analysis. J. Am. Heart Assoc.5, e002530 (2016).
doi: 10.1161/JAHA.115.002530 pubmed: 26811160 pmcid: 4859370
Aimo, A. et al. Clinical and prognostic significance of sST2 in Heart failure. J. Am. Coll. Cardiol.74, 2193–2203. (2019).
doi: 10.1016/j.jacc.2019.08.1039 pubmed: 31648713
Asleh, R. et al. Galectin-3 levels and outcomes after myocardial infarction. J. Am. Coll. Cardiol.73, 2286–2295. (2019).
doi: 10.1016/j.jacc.2019.02.046 pubmed: 31072572 pmcid: 6512841
Nishikimi, T. et al. Increased plasma levels of adrenomedullin in patients with heart failure. J. Am. Coll. Cardiol.26, 1424–1431 (1995).
doi: 10.1016/0735-1097(95)00338-X pubmed: 7594065
Castiglione, V. et al. Biomarkers for the diagnosis and management of heart failure. Heart Fail. Rev.27, 625–643 (2022).
doi: 10.1007/s10741-021-10105-w pubmed: 33852110
Steyerberg, E. W. & Harrell, F. E. Prediction models need appropriate internal, internal-external, and external validation. J. Clin. Epidemiol.69, 245–247 (2016).
doi: 10.1016/j.jclinepi.2015.04.005 pubmed: 25981519
Heinze, G., Wallisch, C. & Dunkler, D. Variable selection – a review and recommendations for the practicing statistician. Biom. J.60, 431–449 (2018).
doi: 10.1002/bimj.201700067 pubmed: 29292533 pmcid: 5969114
Saito, T. & Rehmsmeier, M. The Precision-Recall plot is more informative than the ROC plot when evaluating Binary classifiers on Imbalanced datasets. PLOS ONE. 10, e0118432 (2015).
doi: 10.1371/journal.pone.0118432 pubmed: 25738806 pmcid: 4349800
Collins, G. S. et al. Evaluation of clinical prediction models (part 1): from development to external validation. BMJ. 384, e074819 (2024).
doi: 10.1136/bmj-2023-074819 pubmed: 38191193 pmcid: 10772854
Gardner, D. G., Chen, S., Glenn, D. J. & Grigsby, C. L. Molecular Biology of the natriuretic peptide system. Hypertension. 49, 419–426 (2007).
doi: 10.1161/01.HYP.0000258532.07418.fa pubmed: 17283251
Omland, T., Aakvaag, A. & Vik-Mo, H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart. 76, 232–237 (1996).
doi: 10.1136/hrt.76.3.232 pubmed: 8868981 pmcid: 484512
Rogers, R. K., May, H. T., Anderson, J. L. & Muhlestein, J. B. Prognostic value of B-type natriuretic peptide for cardiovascular events independent of left ventricular end-diastolic pressure. Am. Heart J.158, 777–783 (2009).
doi: 10.1016/j.ahj.2009.09.002 pubmed: 19853697
Januzzi, J. L. et al. Measurement of the Interleukin Family Member ST2 in patients with Acute Dyspnea: results from the PRIDE (pro-brain natriuretic peptide investigation of Dyspnea in the Emergency Department) Study. J. Am. Coll. Cardiol.50, 607–613 (2007).
doi: 10.1016/j.jacc.2007.05.014 pubmed: 17692745
Bartunek, J. et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J. Am. Coll. Cardiol.52, 2166–2174 (2008).
doi: 10.1016/j.jacc.2008.09.027 pubmed: 19095135 pmcid: 2637465
Wu, C. K. et al. Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices. Sci. Rep.5, 17007 (2015).
doi: 10.1038/srep17007 pubmed: 26582585 pmcid: 4652206
Bayes, G. et al. Head-to-Head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification. J. Am. Coll. Cardiol.63, 158–166 (2014).
doi: 10.1016/j.jacc.2013.07.087
Andersen, M. J. et al. Relationships between biomarkers and left ventricular filling pressures at Rest and during Exercise in patients after myocardial infarction. J. Card. Fail.20, 959–967 (2014).
doi: 10.1016/j.cardfail.2014.09.012 pubmed: 25285749
Nagueh, S. F. et al. Recommendations for the evaluation of left ventricular diastolic function by Echocardiography. Eur. J. Echocardiogr.10, 165–193 (2009).
doi: 10.1093/ejechocard/jep007
van de Bovenkamp, A. A. et al. Validation of the 2016 ASE/EACVI Guideline for Diastolic Dysfunction in patients with unexplained Dyspnea and a preserved left ventricular ejection Fraction. J. Am. Heart Assoc.10, e021165 (2021).
doi: 10.1161/JAHA.121.021165
Oh, J. K., Miranda, W. R., Bird, J. G., Kane, G. C. & Nagueh, S. F. The 2016 diastolic function Guideline. JACC: Cardiovasc. Imaging. 13, 327–335 (2020).
pubmed: 31918901
Nagueh, S. F. & Khan, S. U. Left atrial strain for Assessment of Left ventricular diastolic function. JACC: Cardiovasc. Imaging. 16, 691–707 (2023).
pubmed: 36752445
Rimbas, R. C. et al. New insights into the potential utility of the left atrial function analysis in heart failure with preserved ejection fraction diagnosis. PLoS One. 17, e0267962 (2022).
doi: 10.1371/journal.pone.0267962 pubmed: 35507565 pmcid: 9067684
Monge Garcia, M. I. et al. Performance comparison of ventricular and arterial dP/dtmax for assessing left ventricular systolic function during different experimental loading and contractile conditions. Crit. Care. 22, 325 (2018).
doi: 10.1186/s13054-018-2260-1 pubmed: 30486866 pmcid: 6262953
Ostadal, P., Vondrakova, D., Krüger, A., Janotka, M. & Naar, J. Continual measurement of arterial dP/dtmax enables minimally invasive monitoring of left ventricular contractility in patients with acute heart failure. Crit. Care. 23, 364 (2019).
doi: 10.1186/s13054-019-2654-8 pubmed: 31752966 pmcid: 6869259
Tartière, J. M. et al. Noninvasively determined radial dP/dt is a predictor of mortality in patients with heart failure. Am. Heart J.155, 758–763 (2008).
doi: 10.1016/j.ahj.2007.11.030 pubmed: 18371489
Sohal, M. et al. A multicenter prospective randomized controlled trial of cardiac resynchronization therapy guided by invasive dP/dt. Heart Rhythm O. 22, 19–27 (2021).
doi: 10.1016/j.hroo.2021.01.005

Auteurs

Paul-Adrian Călburean (PA)

Emergency Institute for Cardiovascular Diseases and Transplantation Târgu Mureş, Târgu Mureş, Romania. calbureanpaul@gmail.com.
George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Gheorghe Marinescu Street, No. 38, Târgu Mureş, Romania. calbureanpaul@gmail.com.

Silvia Lupu (S)

Emergency Institute for Cardiovascular Diseases and Transplantation Târgu Mureş, Târgu Mureş, Romania.
George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Gheorghe Marinescu Street, No. 38, Târgu Mureş, Romania.

Adina Huțanu (A)

George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Gheorghe Marinescu Street, No. 38, Târgu Mureş, Romania.

Mădălina Oprica (M)

George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Gheorghe Marinescu Street, No. 38, Târgu Mureş, Romania.

Diana Roxana Opriș (DR)

Emergency Institute for Cardiovascular Diseases and Transplantation Târgu Mureş, Târgu Mureş, Romania.
George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Gheorghe Marinescu Street, No. 38, Târgu Mureş, Romania.

Alexandru Stan (A)

Emergency Institute for Cardiovascular Diseases and Transplantation Târgu Mureş, Târgu Mureş, Romania.
George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Gheorghe Marinescu Street, No. 38, Târgu Mureş, Romania.

Anda-Cristina Scurtu (AC)

Emergency Institute for Cardiovascular Diseases and Transplantation Târgu Mureş, Târgu Mureş, Romania.
George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Gheorghe Marinescu Street, No. 38, Târgu Mureş, Romania.

David Aniței (D)

Emergency Institute for Cardiovascular Diseases and Transplantation Târgu Mureş, Târgu Mureş, Romania.

Marius Harpa (M)

Emergency Institute for Cardiovascular Diseases and Transplantation Târgu Mureş, Târgu Mureş, Romania.
George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Gheorghe Marinescu Street, No. 38, Târgu Mureş, Romania.

Klara Brînzaniuc (K)

Emergency Institute for Cardiovascular Diseases and Transplantation Târgu Mureş, Târgu Mureş, Romania.
George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Gheorghe Marinescu Street, No. 38, Târgu Mureş, Romania.

Horațiu Suciu (H)

Emergency Institute for Cardiovascular Diseases and Transplantation Târgu Mureş, Târgu Mureş, Romania.
George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Gheorghe Marinescu Street, No. 38, Târgu Mureş, Romania.

László Hadadi (L)

Emergency Institute for Cardiovascular Diseases and Transplantation Târgu Mureş, Târgu Mureş, Romania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH